[THE INVESTOR] Celltrion said on Feb. 8 that Chairman Seo Jung-jin will map out a three-year sales plan for biosimilar products and unveil new drug pipelines to 25 marketing partner companies during an annual meeting to be held in Italy.
Some 110 executives from global pharma firms including Mundipharma and Nippon Kayaku will attend the 2018 Celltrion Healthcare International Summit that runs from Feb. 8-9.
Celltrion Chairman Seo Jung-jin
The main agenda will be the sales performance review of Celltrion’s flagship products Remsima and Truxima and future marketing strategy for Herzuma, which is expected to receive approval from the European Commission in the first half of this year.
Celltrion and its marketing affiliate Celltrion Healthcare said they are planning “systematic and aggressive marketing tactics” to reach their three-year sales targets set until 2020.
“As Remsima and Truxima have achieved sales exceeding the market estimation and successfully settled in the global market, the partners have high expectations for the launching of Herzuma,” a Celltrion Healthcare official said.
Celltrion Healthcare has been adopting different marketing strategies based on market conditions and past experiences. For Remsima, it signed co-exclusive agreements with multiple sales partners, which led to a significant gain in market share to nearly 50 percent in Europe. For the US, however, it chose Pfizer as a sole partner for the drug after experiencing price erosion in Europe.
The company will share its plan for the third plant that will be built outside of Korea with a capacity of 360,000 liters and other ways to enhance price competitiveness and improve convenience for patients. Drug pipelines that Celltrion aims to commercialize by 2030 will also be unveiled during the meeting, it said.
By Park Han-na (firstname.lastname@example.org)